Vittia (VITT3) Q4 2024 earnings summary

Executive summary

• Net revenue grew 4.0% in 2024, reversing the prior year's decline, with Q4 net revenue at R$255.8 million, up 5.1% year-over-year, despite sector challenges and tighter credit.

• Adjusted EBITDA was R$133.3 million in 2024, down 6.0% year-over-year, but Q4 adjusted EBITDA rose 36.9% to R$61.3 million.

• Net income for 2024 was R$75.3 million, down 22.6% from 2023, with Q4 net income at R$46.4 million, up 12.4% year-over-year.

• Strategic focus on cost discipline, innovation, and efficiency, with 13 new biological recommendations and the launch of Triunfe.

• Maintained a robust capital structure, with net debt/EBITDA at 1.09x and continued shareholder returns through dividends and buybacks.

Financial highlights

• Net revenue reached R$786.6 million in 2024 (+4.0% vs. 2023); Q4 net revenue was R$255.8 million (+5.1% vs. Q4 2023).

• Adjusted EBITDA was R$133.3 million in 2024 (-6.0% vs. 2023), with a margin of 16.9%; Q4 adjusted EBITDA was R$61.3 million (+36.9% vs. Q4 2023).

• Net income was R$75.3 million in 2024 (-22.6% vs. 2023); Q4 net income was R$46.4 million (+12.4% vs. Q4 2023).

• Capex was R$32.8 million in 2024 (-34.7% vs. 2023); Q4 Capex was R$6.2 million (-48.1% vs. Q4 2023).

• Gross margin for 2024 was 33.8% (-2.6 p.p. vs. 2023); Q4 gross margin was 36.9% (+2.0 p.p. vs. Q4 2023).

Outlook and guidance

• Entering 2025 with improved fundamentals: favorable exchange rates, low input prices, and a solid financial position.

• Management expects a recovery in key financial metrics, with a focus on efficiency, innovation, and leveraging a robust balance sheet.

• No significant CAPEX planned for the short term due to current excess capacity in the biologicals plant.

• New product launches, especially in biologicals, are expected to contribute more significantly from 2026.

• Credit market remains tight, but the company is positioned to benefit from its strong financial standing.